Laura Gómez-Cuadrado

Dr. Laura Gómez-Cuadrado

Mogrify
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Cell
Verified
Journal Article
Open access
ASAlan Serrels
Alan Serrels
TLTom Lund
Tom Lund
BSBryan Serrels
Bryan Serrels
ABAdam Byron
Adam Byron
RMRhoanne C. McPherson
Rhoanne C. McPherson
MFMargaret C. Frame
Margaret C. Frame
Focal adhesion kinase (FAK) promotes anti-tumor immune evasion. Specifically, the kinase activity of nuclear-targeted FAK in squamous cell carcinoma (SCC) cells drives exhaustion of CD8(+) T cells and recruitment of regulatory T cells (Tregs) in the tumor microenvironment by regulating chemokine/cytokine and ligand-receptor networks, including via transcription of Ccl5, which is crucial. These changes inhibit antigen-primed cytotoxic CD8(+) T cell activity, permitting growth of FAK-expressing tumors. Mechanistically, nuclear FAK is associated with chromatin and exists in complex with transcription factors and their upstream regulators that control Ccl5 expression. Furthermore, FAK's immuno-modulatory nuclear activities may be specific to cancerous squamous epithelial cells, as normal keratinocytes do not have nuclear FAK. Finally, we show that a small-molecule FAK kinase inhibitor, VS-4718, which is currently in clinical development, also drives depletion of Tregs and promotes a CD8(+) T cell-mediated anti-tumor response. Therefore, FAK inhibitors may trigger immune-mediated tumor regression, providing previously unrecognized therapeutic opportunities.

1 September 2017 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
LGLaura Gómez-Cuadrado
Laura Gómez-Cuadrado
NTNatasha Tracey
Natasha Tracey
RMRuoyu Ma
Ruoyu Ma
BQBinzhi Qian
Binzhi Qian
VBValerie G. Brunton
Valerie G. Brunton
Metastasis is the spread of cancer cells from a primary tumor to distant sites within the body to establish secondary tumors. Although this is an inefficient process, the consequences are devastating as metastatic disease accounts for >90% of cancer-related deaths. The formation of metastases is the result of a series of events that allow cancer cells to escape from the primary site, survive in the lymphatic system or blood vessels, extravasate and grow at distant sites. The metastatic capacity of a tumor is determined by genetic and epigenetic changes within the cancer cells as well as contributions from cells in the tumor microenvironment. Mouse models have proven to be an important tool for unraveling the complex interactions involved in the metastatic cascade and delineating its many stages. Here, we critically appraise the strengths and weaknesses of the current mouse models and highlight the recent advances that have been made using these models in our understanding of metastasis. We also discuss the use of these models for testing potential therapies and the challenges associated with the translation of these findings into the provision of new and effective treatments for cancer patients.

1 October 2017 in Cell Reports
Verified
Journal Article
Open access
LNLaura Novellasdemunt
Laura Novellasdemunt
Valentina FoglizzoValentina Foglizzo
Valentina Foglizzo
LGLaura Gómez-Cuadrado
Laura Gómez-Cuadrado
PAPedro Antas
Pedro Antas
AKAnna Kucharska
Anna Kucharska
VLVivian S.W. Li
Vivian S.W. Li
The tumor suppressor gene adenomatous polyposis coli (APC) is mutated in most colorectal cancers (CRCs), resulting in constitutive Wnt activation. To understand the Wnt-activating mechanism of the APC mutation, we applied CRISPR/Cas9 technology to engineer various APC-truncated isogenic lines. We find that the β-catenin inhibitory domain (CID) in APC represents the threshold for pathological levels of Wnt activation and tumor transformation. Mechanistically, CID-deleted APC truncation promotes β-catenin deubiquitination through reverse binding of β-TrCP and USP7 to the destruction complex. USP7 depletion in APC-mutated CRC inhibits Wnt activation by restoring β-catenin ubiquitination, drives differentiation, and suppresses xenograft tumor growth. Finally, the Wnt-activating role of USP7 is specific to APC mutations; thus, it can be used as a tumor-specific therapeutic target for most CRCs.

18 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KTKaty Teo
Katy Teo
LGLaura Gómez-Cuadrado
Laura Gómez-Cuadrado
MTMilou Tenhagen
Milou Tenhagen
ABAdam Byron
Adam Byron
MRMax Rätze
Max Rätze
PDPatrick W. B. Derksen
Patrick W. B. Derksen
Despite the fact that loss of E-cadherin is causal to the development and progression of invasive lobular carcinoma (ILC), options to treat this major breast cancer subtype are limited if tumours develop resistance to anti-oestrogen treatment regimens. This study aimed to identify clinically targetable pathways that are aberrantly active downstream of E-cadherin loss in ILC. Using a combination of reverse-phase protein array (RPPA) analyses, mRNA sequencing, conditioned medium growth assays and CRISPR/Cas9-based knock-out experiments, we demonstrate that E-cadherin loss causes increased responsiveness to autocrine growth factor receptor (GFR)-dependent activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt signalling. Autocrine activation of GFR signalling and its downstream PI3K/Akt hub was independent of oncogenic mutations in PIK3CA, AKT1 or PTEN. Analyses of human ILC samples confirmed growth factor production and pathway activity. Pharmacological inhibition of Akt using AZD5363 or MK2206 resulted in robust inhibition of cell growth and survival of ILC cells, and impeded tumour growth in a mouse ILC model. Because E-cadherin loss evokes hypersensitisation of PI3K/Akt activation independent of oncogenic mutations in this pathway, we propose clinical intervention of PI3K/Akt in ILC based on functional E-cadherin inactivation, irrespective of activating pathway mutations.

11 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
HCHelen Creedon
Helen Creedon
LGLaura Gómez-Cuadrado
Laura Gómez-Cuadrado
ŽTŽygimantė Tarnauskaitė
Žygimantė Tarnauskaitė
JBJozef Balla
Jozef Balla
MCMarta Canel
Marta Canel
VBValerie G. Brunton
Valerie G. Brunton
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy

11 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LGLaura Gómez-Cuadrado
Laura Gómez-Cuadrado
EBEsme Bullock
Esme Bullock
ZMZeanap Mabruk
Zeanap Mabruk
HZHong Zhao
Hong Zhao
MSMargarita Souleimanova
Margarita Souleimanova
VBValerie G. Brunton
Valerie G. Brunton
Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer, and it exhibits a number of clinico-pathological characteristics distinct from the more common invasive ductal carcinoma (IDC). We set out to identify alterations in the tumor microenvironment (TME) of ILC. We used laser-capture microdissection to separate tumor epithelium from stroma in 23 ER+ ILC primary tumors. Gene expression analysis identified 45 genes involved in regulation of the extracellular matrix (ECM) that were enriched in the non-immune stroma of ILC, but not in non-immune stroma from ER+ IDC or normal breast. Of these, 10 were expressed in cancer-associated fibroblasts (CAFs) and were increased in ILC compared to IDC in bulk gene expression datasets, with PAPPA and TIMP2 being associated with better survival in ILC but not IDC. PAPPA, a gene involved in IGF-1 signaling, was the most enriched in the stroma compared to the tumor epithelial compartment in ILC. Analysis of PAPPA- and IGF1-associated genes identified a paracrine signaling pathway, and active PAPP-A was shown to be secreted from primary CAFs. This is the first study to demonstrate molecular differences in the TME between ILC and IDC identifying differences in matrix organization and growth factor signaling pathways.